Catalyst Biosciences Stock News

Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?

Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale

Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "Thi

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

Biogen (BIIB) and Catalyst Biosciences (CBIO) have ended their collaboration on potential treatments for dry AMD (dAMD), a leading cause of blindness.Per the terms of the agreement,…

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments. "We are delighted to regain the rights to CB 2782-PEG which unlocks the full potential of our complement proteases in ophthalmology. We now have two wholly-owned, potentially best-in-class development candidates, CB 2782-PEG and CB 4332, a long half-life complement factor I fusion, each targeting clinically validated mechanisms in dry AMD. Dry AMD, a leading cause of blindness in its severe form for which there are no currently approved drugs, represents a significant market opportunity, estimated at over $10B," said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. About Catalyst Biosciences, the Protease Medicines …

Although US crude futures fell over 2% on Thursday, there were a few notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Catalyst Biosciences The Trade: Catalyst Biosciences, Inc. (NASDAQ: CBIO ) Chief Scientific Officer Grant E Blouse acquired a total of 3,250 shares at an average price of $0.46. To acquire these shares, it cost $1.5 thousand. What’s Happening: Catalyst Biosciences, last month, received rare pediatric disease designation for CB 4332 for the treatment of CFI deficiency. What Catalyst Biosciences Does: Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions …

Catalyst Biosciences Inc. (NASDAQ:CBIO)s traded shares stood at 1.0 million during the last session, with the companys beta value hitting 2.01. At the close of trading, the stocks price was $0.56, to imply an increase of 1.21% or $0.01 in intraday trading. The CBIO shares 52-week high remains $7.55, putting it -1248.21% down since that Catalyst Biosciences Inc. (NASDAQ: CBIO): Can A Stock Be -38.80% Lower Year-To-Date And Still Be A Loser? Read More »

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.

NEW YORK , Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APM, F, NOK, CBIO, and GE. … Full story available on Benzinga.com

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID). "The granting of the Rare Pediatric Disease Designation for CB 4332 underscores the significant unmet medical need in pediatric patients with CFID. We are focused on efficiently advancing the development of CB 4332 and our complement medicines portfolio in a number of complement-driven diseases in hematology, nephrology and ophthalmology. We are pleased with the FDA''s assessment of CB 4332 as a potential therapy for underserved pediatric patients with CFID and the granting of the RPDD," said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. Under the FDA''s rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease.

Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalyst Biosciences Inc (CBIO) shares closed today at 0.5% above its 52 week low of $0.83, giving the company a market cap of $26M. The stock is currently down 8.5% year-to-date, down 86.5% over the past 12 months, and down 91.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 34.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.5% The company's stock price performance over the past 12 months lags the peer average by 507.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) with the stream of -1.42% also noticed, India Isoray, Inc. (AMEX:ISR) encountered a rapid change of -1.45% in the last hour of Tuesdays trading session. Catalyst The post Have a gripe on this: Catalyst Biosciences, Inc. (NASDAQ:CBIO), Isoray, Inc. (AMEX:ISR) appeared first on Stocks Equity .